http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 09:07:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488 http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html <p>ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Jim Yong Kim has joined the company as vice chairman, according to a company press release. He will serve within a newly created Office of the Executive Chairman and report to founder and Executive Chairman Dr. Patrick Soon-Shiong.</p> <p>In his role, Dr. Kim will focus on building relationships with governments, health ministries, multilateral institutions, and global health partners to support access to the company's immunotherapy platform and approved therapies in markets outside the United States.</p> <p>Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. In 1987, he co-founded http://www.streetinsider.com/Management+Changes/ImmunityBio+names+former+World+Bank+president+Jim+Yong+Kim+as+vice+chairman/26895334.html Mon, 10 Aug 2026 09:01:10 -0400 A.17568957 A.31896609 A.33696197 A.35954321 A.50201689 A.60012009 IBRX O.04889877 O.07647695 O.15639564 O.20042353 O.20102570 O.20737027 O.25176488